Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 1998

View Archived Issues

Preclinical and clinical results for liposomal cisplatin presented at AACR meeting

New hormonal agents discussed at cancer meeting

Protein farnesyltransferase inhibitors: preclinical studies reported at AACR

Senetek will present additional INVICORP clinical data at AUA annual meeting

Peptimmune and Peptide Therapeutics form asthma, autoimmune disease collaboration

Demeter granted U.S. patent for peptide stabilization

Canadian notice of patent allowance for Imutec's Virulizin

Detrol approved by FDA for overactive bladder

NIH offers gene expression detection technology for licensing

Another antimigraine option now available for sufferers in U.S.

U.S. patent issues for Immunex's soluble CD40 ligand

Cytokine inhibitors claimed by Novo Nordisk for diabetes and other disorders

Antimuscarinic piperidines described by Schering-Plough

Novel fusion protein with potent activity in colon cancer models reported at AACR

Adenosine derivatives for cardiovascular, lipid disorders

Extensive preclinical and clinical results presented for Bayer MMP inhibitor

New ocular agents described by Novartis

SKB develops new agents for osteoporosis and related disorders

Dendreon's dendritic cell-based immunotherapy reported at AACR

Focus on agents for estrogen deprivation continues at Lilly

KRH-594 evaluated in animal models of nephropathy, vascular hyperplasia

Karenitecins: BioNumerik's fourth-generation camptothecin derivatives

FDA approves Viagra; first oral treatment for ED on the way to market

IND filed for tissue-selective estrogen compound

XNA-2: a new treatment for skin disorders available for licensing from Xenna

Z-335 demonstrates beneficial effects in models of peripheral circulatory insufficiency

Revive: a topical treatment for androgenic alopecia available for licensing

Platelet antiaggregatory effects of liposome-encapsulated streptokinase

NC-100100 enhances myocardial infarction imaging in dogs

Excitatory amino acid receptor antagonists related to PNQX reported at ACS

U.S. universities develop new agents for PCP